Studies of calprotectin levels in synovial fluid in patients with RA. Values are mean (SD) or median (range) unless otherwise specified.
| Study | Disease Duration, Yrs | n | Sample | Calprotectin, µg/l | Correlation with Blood Levels | Controls | n | Control Levels | Concomitant Treatment |
|---|---|---|---|---|---|---|---|---|---|
| Berntzen, et al25 | 5 (3 mos–45 yrs) | 41 | Knee | 18,156 (1951–375,368) | r = 0.52, p < 0.001 | OA | 6 | 895 (290–2014) | DMARD, NSAID |
| Burmeister, et al28 | NR | 11 | NR | 1,739,081 (2,640,000) | NR | OA | 17 | 28887 (23032) | NR |
| Drynda, et al30 | NR | 23 | NR | 475,000 (280,077) | r = 0.63, p = 0.007 | OA | 23 | 970 (26377) | NR |
| De Rycke, et al31 | 7 (0.2–30) | 20 | Knee | 25,838 (234–234,431) | r = 0.65, p = 0.004 | SpA | 20 | 8659 (93–49698) | DMARD, GC |
| Sunahori, et al32 | NR | 17 | Knee | 54,800 (7200) | NR | OA | 17 | 7300 (4500) | DMARD, GC |
RA: rheumatoid arthritis; OA: osteoarthritis; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs; NR: not reported; SpA: spondyloarthritis; GC: glucocorticoids.